Sage Therapeutics Inc. (NASDAQ:SAGE) shares fell to a low of $55.40 before closing at $57.44. Intraday shares traded counted 1.16 million, which was -59.25% lower than its 30-day average trading volume of 728.89K. SAGE’s previous close was $56.88 while the outstanding shares total 58.37M. The firm has a beta of 2.02, a 12-month trailing P/E ratio of 5.20, and a growth ratio of 0.13. The stock’s Relative Strength Index (RSI) is 34.72, with weekly volatility at 8.11% and ATR at 4.02. The SAGE stock’s 52-week price range has touched low of $39.61 and a $98.39 high. The stock traded higher over the last trading session, gaining 0.98% on 06/21/21.
Investors have identified the Biotechnology company Sage Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $3.26 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Sage Therapeutics Inc. (SAGE) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 2.05 billion total, with 62.01 million as their total liabilities.
SAGE were able to record -109.09 million as free cash flow during the 08/10/2021 quarter of the year, this saw their quarterly net cash flow reduce by -762.28 million. In cash movements, the company had a total of -109.09 million as operating cash flow.
Potential earnings growth for Sage Therapeutics Inc. (SAGE)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/10/2021 quarter of the year, Sage Therapeutics Inc. recorded a total of 1.58 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -44.41% coming in sequential stages and their sales for the 08/10/2021 quarter reducing by -69968.6%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 0.19 million trying to sell their products during the last quarter, with the result yielding a gross income of 1.4 million. This allows shareholders to hold on to 58.37M with the recently reported earning now reading -1.64 cents per share. This is a figure that compared to analyst’s prediction for their 08/10/2021 (-1.64 cents a share).
Having a look at the company’s valuation, the company is expected to record -6.02 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SAGE sounds very interesting.
Is the stock of SAGE attractive?
In related news, Director, FRATES JAMES M bought 1,810 shares of the company’s stock in a transaction that recorded on Jun 16. The purchase was performed at an average price of 55.10, for a total value of 99,735. As the purchase deal closes, the President and CEO, Greene Barry E now bought 8,800 shares of the company’s stock, valued at 495,627. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
11 out of 22 analysts covering the stock have rated it a Buy, while 11 have maintained a Hold recommendation on Sage Therapeutics Inc.. 0 analysts has assigned a Sell rating on the SAGE stock. The 12-month mean consensus price target for the company’s shares has been set at $93.42.